MedTrace Logo

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

NCT04039516 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-04

No results posted yet for this study

Summary

Randomised trial to assess progression of carcinoid heart disease in patients treated with Lutathera therapy compared to best supportive care.

Conditions

  • Carcinoid Heart Disease
  • Carcinoid Syndrome
  • Carcinoid Tumor

Interventions

DRUG

Lutathera

A total of 4 infusions of Lutathera to be administered every 8 weeks.

Sponsors & Collaborators

  • Advanced Accelerator Applications

    collaborator INDUSTRY

  • King's College Hospital NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-31
Primary Completion
2024-11-30
Completion
2024-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04039516 on ClinicalTrials.gov